Boston Scientific Corp. (BSX) Tops Q3 EPS by 5c; Issues Mixed Guidance
Boston Scientific Corp. (NYSE: BSX) reported Q3 EPS of $0.16, $0.05 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.74 billion versus the consensus estimate of $1.76 billion.
Boston Scientific Corp. sees FY2012 EPS of $0.63-0.66, which may not compare consensus of $0.42. Boston Scientific Corp. sees FY2012 revenue of $7.17-7.24 billion, versus the consensus of $7.26 billion.
Boston Scientific Corp. sees Q4 2012 EPS of $0.06-0.09, versus the consensus of $0.12. Boston Scientific Corp. sees Q4 2012 revenue of $1.74-1.82 billion, versus the consensus of $1.8 billion.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees FY2012 EPS of $0.63-0.66, which may not compare consensus of $0.42. Boston Scientific Corp. sees FY2012 revenue of $7.17-7.24 billion, versus the consensus of $7.26 billion.
Boston Scientific Corp. sees Q4 2012 EPS of $0.06-0.09, versus the consensus of $0.12. Boston Scientific Corp. sees Q4 2012 revenue of $1.74-1.82 billion, versus the consensus of $1.8 billion.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.